查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830850

2025年全球肿瘤辅助药物市场报告

Oncology Adjuvants Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，肿瘤辅助治疗市场呈现强劲成长势头，预计将从2024年的15.2亿美元成长到2025年的16.3亿美元，复合年增长率达7.6%。这段时期的成长主要受以下因素驱动：全球癌症发生率上升、对临床前试验可预测性要求提高、患者来源异种移植（PDX）模型应用日益广泛、对体内疗效数据依赖性增强以及对早期免疫肿瘤学研究的日益重视。

预计未来几年肿瘤辅助药物市场规模将维持强劲成长，2029年将达到21.7亿美元，复合年增长率（CAGR）为7.3%。预测期内的增长可归因于以下因素：对与人类相关的模型的日益关注、对精准肿瘤学需求的增长、免疫肿瘤疗法的发展、对高通量筛检模型的需求不断增长以及对罕见癌症模型的兴趣日益浓厚。这段时期的关键趋势包括奈米技术的整合、用于增强CAR-T细胞疗法的辅助药物的开发、免疫肿瘤辅助药物的进步以及人工智慧和机器学习的应用。

肿瘤辅助治疗是指与癌症主要治疗同时进行的药物或疗法，旨在透过增强免疫反应、降低肿瘤抗药性和辅助症状管理，提高癌症治疗的疗效、减少副作用并改善患者预后。这些治疗方法的目标是为癌症治疗提供更全面、更个人化的治疗方法。

肿瘤辅助治疗药物主要分为化疗辅助药物、放射线治疗辅助药物、免疫治疗辅助药物、荷尔蒙疗法辅助药物、标靶治疗辅助药物。化疗辅助药物是指与第一线化疗合併使用的药物或物质，旨在提高疗效、减少副作用并增强身体对癌症治疗的反应。这些辅助药物的给药途径多种多样，包括口服、静脉注射、皮下注射、局部和肌肉注射。它们适用于多种适应症，包括乳癌、神经胶母细胞瘤、肺癌、结直肠癌、卵巢癌、肉瘤和前列腺癌，并被包括癌症研究机构和专科肿瘤医院在内的主要终端用户广泛使用。

2025年春季美国突然提高关税及其引发的贸易摩擦对製药公司造成了严重衝击，这些公司正面临原料药、玻璃瓶和实验室设备等产品的关税问题。利润率高的学名药生产商尤其脆弱，一些公司不得不缩减低收益药物的生产规模。生物技术公司也因关税导致的特种试剂短缺而面临临床试验延期。为了应对这一局面，製药业正在印度和欧洲扩大原料药的生产，增加库存，并游说政府对基本药物给予贸易豁免。

这份肿瘤辅助药物市场研究报告是商业研究公司最新发布的系列报告之一，提供肿瘤辅助药物市场统计数据，例如全球市场规模、区域份额、竞争对手及其市场份额、市场细分、市场趋势以及肿瘤辅助药物行业的商机。本报告对肿瘤辅助药物产业的现状和未来发展趋势进行了详细分析，为您提供所需的一切全面资讯。

未来几年，对个人化医疗日益增长的需求预计将推动肿瘤辅助治疗市场的成长。个人化医疗根据患者的基因谱和生活方式量身定制治疗方案，在提高疗效的同时最大限度地减少副作用。基因和分子谱分析技术的进步使医疗服务提供者能够根据患者肿瘤的特征，设计特异性针对残留癌细胞的肿瘤辅助性治疗。例如，个人化医疗联盟在2023年2月报告称，2022年共有12种新的个人化疗法核准，约占所有新核准疗法的34%，显示个人化疗法的应用显着增加。这种对个人化医疗日益增长的关注正在推动肿瘤辅助治疗市场的发展。

肿瘤辅助治疗市场的企业正在推动辅助性治疗免疫查核点抑制剂等疗法的研发。免疫查核点抑制剂能够阻断PD-1、PD-L1和CTLA-4等通常抑制免疫活性的蛋白质，使T细胞能够更有效地攻击癌细胞。例如，默克公司于2023年1月推出了KEYTRUDA（Pembrolizumab），用于手术和含铂类药物辅助性治疗。 化疗透过抑制PD-1受体，恢復免疫系统对癌细胞的识别，从而降低復发风险，提高总存活期，并支持癌症治疗的个人化方案。

2022年5月，总部位于挪威的临床阶段免疫肿瘤公司Targovax ASA与总部位于美国的Agenus Inc.达成合作，共同推动ONCOS-102黑色素瘤免疫疗法临床试验。此次合作将双方在肿瘤辅助治疗和免疫疗法领域的专业知识相结合，旨在评估ONCOS-102治疗黑色素瘤的安全性和有效性，并透过创新的标靶免疫疗法策略改善患者的治疗效果。

肿瘤辅助治疗市场由提供治疗增强、副作用减少、肿瘤抗药性预防和个人化治疗优化等服务的营业单位所获得的收益所构成。市场价值还包括服务提供者销售的或包含在其服务产品中的相关产品的价值。肿瘤辅助治疗市场还包括营养辅助剂、基因治疗辅助剂、溶瘤病毒辅助剂和热疗辅助剂的销售。该市场的价值为“出厂价”，即产品製造商或生产商销售的产品价值，无论销售对像是其他营业单位（包括下游製造商、批发商、经销商和零售商）还是直接销售给最终客户。该市场的产品价值还包括产品製造商提供的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球肿瘤辅助治疗：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 终端用户产业分析
  • 全球肿瘤辅助药物市场：成长率分析
  • 全球肿瘤辅助治疗市场表现：规模与成长，2019-2024年
  • 全球肿瘤辅助药物市场预测：规模与成长，2024-2029年，2034年
  • 全球肿瘤辅助药物：潜在市场规模 (TAM)

第六章 市场细分

  • 全球肿瘤辅助药物市场（依辅助药物类型、表现及预测划分，2019-2024年、2024-2029年、2034年）
  • 化疗辅助
  • 放射辅助剂
  • 免疫疗法佐剂
  • 荷尔蒙佐剂
  • 标靶治疗辅助
  • 全球肿瘤辅助药物市场依给药途径、效能及预测划分，2019-2024年、2024-2029年、2034年
  • 口服
  • 静脉
  • 皮下
  • 局部的
  • 肌肉注射
  • 全球肿瘤辅助药物市场依适应症、疗效及预测划分，2019-2024年、2024-2029年、2034年
  • 乳癌
  • 神经胶母细胞瘤
  • 肺癌
  • 大肠直肠癌
  • 卵巢癌
  • 肉瘤
  • 摄护腺癌
  • 其他迹象
  • 全球肿瘤辅助药物市场依最终用户、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 癌症研究所
  • 癌症医院
  • 全球肿瘤辅助药物市场：化疗辅助药物细分（按类型）、表现及预测，2019-2024年、2024-2029年、2034年
  • 烷化剂
  • 抗代谢物
  • 细胞週期蛋白
  • 植物生物碱
  • 拓朴异构酶抑制剂
  • 铂化合物
  • 全球肿瘤辅助治疗市场：依放射辅助治疗（按类型）细分、表现及预测，2019-2024年、2024-2029年、2034年
  • 放射增敏剂
  • 辐射防护器
  • 缺氧细胞敏化剂
  • 去氧核糖核酸（DNA）修復抑制剂
  • 免疫调节剂合併放射线治疗
  • 全球肿瘤佐剂市场：依免疫疗法佐剂（按类型）细分、效能及预测，2019-2024年、2024-2029年、2034年
  • 查核点抑制剂
  • 细胞激素
  • 癌症疫苗
  • 过继性细胞移植
  • 免疫调节剂
  • 全球肿瘤辅助药物市场：依荷尔蒙辅助药物（类型）细分、效能及预测，2019-2024年、2024-2029年、2034年
  • 选择性雌激素受体调节
  • Aromatase抑制剂
  • 促性腺激素分泌释放激素促效剂或拮抗剂
  • 雄性激素受体抑制剂
  • 雌激素受体稳压器
  • 全球肿瘤辅助治疗市场：细分市场（标靶治疗辅助药物，按类型划分）、表现及预测（2019-2024年、2024-2029年、2034年）
  • 蛋白酪氨酸激酶抑制剂（TKI）
  • 蛋白酶体抑制剂
  • 聚（ADP-核糖）聚合酵素（PARP）抑制剂
  • mTOR抑制剂
  • v-Raf 鼠肉瘤病毒癌基因同源物 B (BRAF) 或丝裂原活化蛋白激酶激酶 (MEK) 抑制剂
  • 血管内皮生长因子（VEGF）抑制剂

第七章 区域和国家分析

  • 全球肿瘤辅助药物市场：依地区、绩效及预测划分，2019-2024年、2024-2029年、2034年
  • 全球肿瘤辅助药物市场依国家划分、绩效及预测（2019-2024 年、2024-2029 年、2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

  • 肿瘤辅助治疗市场：竞争格局
  • 肿瘤辅助治疗市场：公司概况
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Novartis AG
  • Eli Lilly And Company
  • Amgen Inc.
  • Regeneron Pharmaceuticals
  • Daiichi Sankyo Company Limited
  • SEPPIC
  • Ipsen SA
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Croda International Plc
  • Dynavax Technologies Corporation
  • Agenus Inc.
  • Aurorium
  • Elicio Therapeutics Inc.

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

  • 2029年肿瘤辅助药物市场：蕴藏新机会的国家
  • 2029年肿瘤辅助药物市场：蕴藏新机会的细分市场
  • 2029年肿瘤辅助药物市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章附录

简介目录
Product Code: r37841

Oncology adjuvants are substances or therapies administered alongside primary cancer treatments to enhance their effectiveness, minimize side effects, and improve patient outcomes by strengthening the immune response, reducing tumor resistance, or assisting in symptom management. They aim to provide a more comprehensive and personalized approach to cancer care.

The key types of oncology adjuvants include chemotherapy adjuvants, radiation adjuvants, immunotherapy adjuvants, hormonal adjuvants, and targeted therapy adjuvants. Chemotherapy adjuvants are drugs or substances used alongside primary chemotherapy treatments to improve efficacy, reduce side effects, or enhance the body's response to cancer therapy. These adjuvants are administered via various routes, including oral, intravenous, subcutaneous, topical, and intramuscular methods. They are applied across multiple indications, such as breast cancer, glioblastoma, lung cancer, colorectal cancer, ovarian cancer, sarcoma, prostate cancer, and others, and are utilized by key end users including cancer research institutes and specialized cancer hospitals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The oncology adjuvants market research report is one of a series of new reports from The Business Research Company that provides oncology adjuvants market statistics, including oncology adjuvants industry global market size, regional shares, competitors with an oncology adjuvants market share, oncology adjuvants market segments, market trends and opportunities, and any further data you may need to thrive in the oncology adjuvants industry. This oncology adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology adjuvants market size has grown strongly in recent years. It will grow from $1.52 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to the rising incidence of cancer worldwide, increasing demand for improved preclinical predictability, growing utilization of patient-derived xenograft (PDX) models, expanding reliance on in vivo efficacy data, and heightened focus on early-stage immuno-oncology research.

The oncology adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the increasing focus on human-relevant models, rising demand for precision oncology, growth in immuno-oncology treatments, increasing need for high-throughput screening models, and expanding interest in rare cancer models. Key trends during this period include the integration of nanotechnology, development of adjuvants enhancing CAR-T cell therapies, advancements in immuno-oncology adjuvants, and the application of artificial intelligence and machine learning.

The increasing demand for personalized medicine is expected to drive the growth of the oncology adjuvants market in the coming years. Personalized medicine tailors treatments based on a patient's genetic profile and lifestyle, improving treatment efficacy while minimizing adverse effects. Advances in genetic and molecular profiling allow healthcare providers to design oncology adjuvant therapies that specifically target residual cancer cells according to the patient's tumor characteristics. For instance, in February 2023, the Personalized Medicine Coalition reported that 12 new personalized medicines approved in 2022 accounted for approximately 34% of all newly approved therapies, demonstrating a notable increase in adoption. This rising focus on individualized treatment is fueling the oncology adjuvants market.

Companies in the oncology adjuvants market are advancing therapies such as immune checkpoint inhibitor adjuvant treatments, which enhance post-surgical outcomes by leveraging the patient's immune system to target remaining tumor cells. Immune checkpoint inhibitors block proteins like PD-1, PD-L1, or CTLA-4 that normally suppress immune activity, thereby allowing T-cells to attack cancer more effectively. For example, in January 2023, Merck & Co., Inc., launched KEYTRUDA (pembrolizumab) as an adjuvant therapy for Stage IB (T2a >=4 cm), II, or IIIA non-small cell lung cancer (NSCLC) following surgery and platinum-based chemotherapy. By blocking the PD-1 receptor, KEYTRUDA restores immune detection of cancer cells, reducing recurrence risk and improving overall survival, while supporting a personalized approach to cancer care.

In May 2022, Targovax ASA, a Norway-based clinical-stage immuno-oncology company, collaborated with US-based Agenus Inc. to advance the ONCOS-102 melanoma immunotherapy trial. This partnership combines expertise in oncology adjuvants and immunotherapy to evaluate ONCOS-102's safety and efficacy in melanoma treatment, aiming to improve patient outcomes through innovative, targeted immunotherapy strategies.

Major players in the oncology adjuvants market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, SEPPIC, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Aurorium, Elicio Therapeutics Inc.

North America was the largest region in the oncology adjuvants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncology adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oncology adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology adjuvants market consists of revenues earned by entities by providing services such as treatment enhancement, side effect reduction, tumor resistance prevention, and personalized therapy optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology adjuvants market also includes sales of nutritional adjuvants, gene therapy adjuvants, oncolytic virus adjuvants, and hyperthermia adjuvants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Adjuvants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology adjuvants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology adjuvants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology adjuvants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type Of Adjuvant: Chemotherapy Adjuvants; Radiation Adjuvants; Immunotherapy Adjuvants; Hormonal Adjuvants; Targeted Therapy Adjuvants
  • 2) By Administration Route: Oral; Intravenous; Subcutaneous; Topical; Intramuscular
  • 3) By Indication: Breast Cancer; Glioblastoma; Lung Cancer; Colorectal Cancer; Ovarian Cancer; Sarcoma; Prostate Cancer; Other Indications
  • 4) By End User: Cancer Research Institute; Cancer Hospitals
  • Subsegments:
  • 1) By Chemotherapy Adjuvants: Alkylating Agents; Antimetabolites; Anthracyclines; Plant Alkaloids; Topoisomerase Inhibitors; Platinum-Based Compounds; Others
  • 2) By Radiation Adjuvants: Radiosensitizers; Radioprotectors; Hypoxic Cell Sensitizers; Deoxyribonucleic Acid (DNA) Repair Inhibitors; Immune Modulating Agents Combined With Radiation
  • 3) By Immunotherapy Adjuvants: Checkpoint Inhibitors; Cytokines; Cancer Vaccines; Adoptive Cell Transfer; Immune Modulating Agents
  • 4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators; Aromatase Inhibitors; Gonadotropin-Releasing Hormone Agonists Or Antagonists; Androgen Receptor Inhibitors; Estrogen Receptor Downregulators
  • 5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Poly (ADP-Ribose) Polymerase (PARP) Inhibitors; mTOR Inhibitors; v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors; Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Eli Lilly And Company; Amgen Inc.; Regeneron Pharmaceuticals; Daiichi Sankyo Company Limited; SEPPIC; Ipsen S.A.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Croda International Plc; Dynavax Technologies Corporation; Agenus Inc.; Aurorium; Elicio Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Adjuvants Market Characteristics

3. Oncology Adjuvants Market Trends And Strategies

4. Oncology Adjuvants Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Oncology Adjuvants Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Oncology Adjuvants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Oncology Adjuvants Market Growth Rate Analysis
  • 5.4. Global Oncology Adjuvants Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Oncology Adjuvants Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Oncology Adjuvants Total Addressable Market (TAM)

6. Oncology Adjuvants Market Segmentation

  • 6.1. Global Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chemotherapy Adjuvants
  • Radiation Adjuvants
  • Immunotherapy Adjuvants
  • Hormonal Adjuvants
  • Targeted Therapy Adjuvants
  • 6.2. Global Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • Subcutaneous
  • Topical
  • Intramuscular
  • 6.3. Global Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Breast Cancer
  • Glioblastoma
  • Lung Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Sarcoma
  • Prostate Cancer
  • Other Indications
  • 6.4. Global Oncology Adjuvants Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Research Institute
  • Cancer Hospitals
  • 6.5. Global Oncology Adjuvants Market, Sub-Segmentation Of Chemotherapy Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alkylating Agents
  • Antimetabolites
  • Anthracyclines
  • Plant Alkaloids
  • Topoisomerase Inhibitors
  • Platinum-Based Compounds
  • 6.6. Global Oncology Adjuvants Market, Sub-Segmentation Of Radiation Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Radiosensitizers
  • Radioprotectors
  • Hypoxic Cell Sensitizers
  • Deoxyribonucleic Acid (DNA) Repair Inhibitors
  • Immune Modulating Agents Combined With Radiation
  • 6.7. Global Oncology Adjuvants Market, Sub-Segmentation Of Immunotherapy Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Checkpoint Inhibitors
  • Cytokines
  • Cancer Vaccines
  • Adoptive Cell Transfer
  • Immune Modulating Agents
  • 6.8. Global Oncology Adjuvants Market, Sub-Segmentation Of Hormonal Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Selective Estrogen Receptor Modulators
  • Aromatase Inhibitors
  • Gonadotropin-Releasing Hormone Agonists Or Antagonists
  • Androgen Receptor Inhibitors
  • Estrogen Receptor Downregulators
  • 6.9. Global Oncology Adjuvants Market, Sub-Segmentation Of Targeted Therapy Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tyrosine Kinase Inhibitors (TKIs)
  • Proteasome Inhibitors
  • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
  • mTOR Inhibitors
  • v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors
  • Vascular Endothelial Growth Factor (VEGF) Inhibitors

7. Oncology Adjuvants Market Regional And Country Analysis

  • 7.1. Global Oncology Adjuvants Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Oncology Adjuvants Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Adjuvants Market

  • 8.1. Asia-Pacific Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Adjuvants Market

  • 9.1. China Oncology Adjuvants Market Overview
  • 9.2. China Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Adjuvants Market

  • 10.1. India Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Adjuvants Market

  • 11.1. Japan Oncology Adjuvants Market Overview
  • 11.2. Japan Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Adjuvants Market

  • 12.1. Australia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Adjuvants Market

  • 13.1. Indonesia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Adjuvants Market

  • 14.1. South Korea Oncology Adjuvants Market Overview
  • 14.2. South Korea Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Adjuvants Market

  • 15.1. Western Europe Oncology Adjuvants Market Overview
  • 15.2. Western Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Adjuvants Market

  • 16.1. UK Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Adjuvants Market

  • 17.1. Germany Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Adjuvants Market

  • 18.1. France Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Adjuvants Market

  • 19.1. Italy Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Adjuvants Market

  • 20.1. Spain Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Adjuvants Market

  • 21.1. Eastern Europe Oncology Adjuvants Market Overview
  • 21.2. Eastern Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Adjuvants Market

  • 22.1. Russia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Adjuvants Market

  • 23.1. North America Oncology Adjuvants Market Overview
  • 23.2. North America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Adjuvants Market

  • 24.1. USA Oncology Adjuvants Market Overview
  • 24.2. USA Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Adjuvants Market

  • 25.1. Canada Oncology Adjuvants Market Overview
  • 25.2. Canada Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Adjuvants Market

  • 26.1. South America Oncology Adjuvants Market Overview
  • 26.2. South America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Adjuvants Market

  • 27.1. Brazil Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Adjuvants Market

  • 28.1. Middle East Oncology Adjuvants Market Overview
  • 28.2. Middle East Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Adjuvants Market

  • 29.1. Africa Oncology Adjuvants Market Overview
  • 29.2. Africa Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Adjuvants Market Competitive Landscape And Company Profiles

  • 30.1. Oncology Adjuvants Market Competitive Landscape
  • 30.2. Oncology Adjuvants Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Adjuvants Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb Company
  • 31.2. AstraZeneca PLC
  • 31.3. Novartis AG
  • 31.4. Eli Lilly And Company
  • 31.5. Amgen Inc.
  • 31.6. Regeneron Pharmaceuticals
  • 31.7. Daiichi Sankyo Company Limited
  • 31.8. SEPPIC
  • 31.9. Ipsen S.A.
  • 31.10. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • 31.11. Croda International Plc
  • 31.12. Dynavax Technologies Corporation
  • 31.13. Agenus Inc.
  • 31.14. Aurorium
  • 31.15. Elicio Therapeutics Inc.

32. Global Oncology Adjuvants Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Adjuvants Market

34. Recent Developments In The Oncology Adjuvants Market

35. Oncology Adjuvants Market High Potential Countries, Segments and Strategies

  • 35.1 Oncology Adjuvants Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Oncology Adjuvants Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Oncology Adjuvants Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer